News

Public · Published

Morgan Stanley maintains Hims & Hers Health at Equal-Weight, lowers price target to $25 from $28

Morgan Stanley kept its Equal-Weight rating on Hims & Hers Health and cut its price target to $25 from $28, a 10.7% decrease. The new target implies 9.0% upside from the stock's Nov. 9 closing price of $22.94.

Published:

Updated:

What happened

Morgan Stanley kept its Equal-Weight rating on Hims & Hers Health and cut its price target to $25 from $28, a 10.7% decrease. The new target implies 9.0% upside from the stock’s Nov. 9 closing price of $22.94.

Confirmed

Global impact / market context

The lower target signals that Morgan Stanley sees less potential value for the shares than before, while retaining its Equal-Weight stance. The stated 9.0% upside is an analyst estimate, not a promised return, and may shape investor expectations rather than company revenue or costs directly.

Analyst inference

This is an analyst rating and valuation update, not a reported change in Hims & Hers Health’s business results, plans, or finances. The article gives one firm’s target and a past closing price, but no wider analyst views or market reaction.

Analyst inference

What to watch

  1. Whether Morgan Stanley changes its Equal-Weight rating or $25 target in a later update, which would show whether its view of the shares has shifted further. Analyst inference
  2. How the shares compare with the $25 target, noting that the article’s 9.0% implied upside uses the Nov. 9 close of $22.94. Analyst inference
  3. Any company results or business announcements that could alter the assumptions behind analyst valuation targets; none are described in this article. Analyst inference

Evidence

  • Original source link unavailable